Abstract:OBJECTIVE:To summarize the clinical characteristics, early diagnosis, comprehensive treatment and prognosis of 6 cases of children with post-transplantation lymphoproliferative disorder (PTLD) after liver transplantation.METHOD:Data of 6 cases with PTLD seen between January 2011 and December 2013 were retrospectively analyzed. The anti-rejection drug dose adjustments, the effect of rituximab, antiviral therapy and comprehensive treatment program after surgery were explored.RESULT:(1) The diagnosis of PTLD was confirmed by histologic findings. Six cases of PTLD including 3 males and 3 females were diagnosed as congenital biliary atresia and underwent split liver transplantation. The occurrence rate of PTLD was 2.9%. (2) The median time to the development of PTLD was less than 6 months. The initial symptom of PTLD in all patients was fever and clinical manifestations of PTLD were non-specific, depending on the involving organs. Five cases of PTLD developed gastrointestinal symptoms, including diarrhea, abdominal pain, and abdominal distension. One case developed respiratory symptoms, including cough and tachypnea. Three cases had lymph node involvement. In 2 cases pathophysiology involved polymorphic lymphocyte proliferation and in 4 cases B lymphocyte proliferation. (3) Two cases died, in whom EBV DNA was not detected and were diagnosed as PTLD by surgical pathology before death. Four survived cases had high EBV-DNA load and then were diagnosed as PTLD by biopsy pathology. (4) Of the 6 cases of PTLD, 2 cases died and 4 cases survived. The overall mortality was 33%. The dead cases were only treated with laparotomy because of intestinal obstruction or perforation and the survived cases were treated with tacrolimus at reduced doses or discontinuation and rituximab. In 2 cases antiviral therapy (acyclovir) was continued, including 1 cases of intestinal obstruction treated with surgical repair. All the survived patients were followed up for 4 months to 1 year and no evidence has been found.CONCLUSION:EBV infection is the high risk factor for PTLD after liver transplantation. Close clinical surveillance of EBV DNA for pediatric liver transplantation was important for the early diagnosis of PTLD. Reducing doses of immunosuppressive agents and rituximab is the initial therapy for PTLD. A reduction in the dose of tacrolimus is suggested. Operation therapy can also play a role in the management of local complications.

Epstein-Barr virus infection after pediatric living related liver transplantation:a fourteen cases analysis

Epstein-Barr Virus Variation in People Living with Human Immunodeficiency Virus in Southeastern China.

Risk factor analysis of EB virus infection after liver transplantation in children with biliary atresia

Clinical analysis of Epstein-Barr virus-associated lymphoproliferative disease in children

Clinical analysis of EB virus infection after hematopoietic stem cell transplantatation

Successful Treatment of Epstein–Barr Virus‐associated Haemophagocytic Syndrome Arising after Living Donor Liver Transplantation

Post-transplant lymphoproliferative disorder associated Epstein-Barr virus DNAemia after liver transplantation in children: Experience from single center

Impact of EBV Infection and Immune Function Assay for Lymphoproliferative Disorder in Pediatric Patients after Liver Transplantation: A Single-Center Experience.

Epstein-Barr virus infection in children with renal transplantation: A single-centre experience

[Clinical Analysis of Epstein-Barr Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation]

The trend of Epstein-Barr virus DNA loads and CD8 + T lymphocyte numbers can predict the prognosis of pediatric liver transplant recipients with PTLD

Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient's blood and oropharynx

Clinical Features and Prognosis of Acute Lymphoblastic Leukemia in Children with Epstein-Barr Virus Infection.

Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient

Risk factors for post-transplant lymphoproliferative disorder after pediatric liver transplantation

Epstein–Barr virus‐associated post‐transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States

Nutrition and Epstein-Barr Viremia in Children Underwent Liver Transplantation: A Retrospective, Cross-Sectional Study

[Early Diagnosis and Comprehensive Treatments of Post-Transplantation Lymphoproliferative Disorder after Pediatric Liver Transplantation].

Diagnosis and Treatment of Post-Transplant Lymphoproliferative Disorder in Pediatric Liver Transplantation: a Report of 3 Cases

Evaluation of early safety of HBcAb-positive donor used on pediatric living donor liver transplant recipients

Long-lasting chronic high load carriage of Epstein-Barr virus is more common in young pediatric renal transplant recipients